LKH Graz
Graz, Styria, 8036, Austria
NCT Number: NCT03460847
Alterations in the intestinal microbiota have been associated to disease pathogenesis in ulcerative colitis. Refractory disease to standard medical therapy as corticosteroids often leads to an unfavourable course in patients suffering from this disorder. This study proposal aims at investigating changes in the intestinal microbiota that can predict a therapy refractory course of ulcerative colitis (UC) and may be used to identify high risk patients in an early phase of their disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Graz, Styria, 8036, Austria
The Investigators suggest that certain alterations in the intestinal microbiota are at least in part responsible for the inability of some patients to response to steroid therapy and probably also for the failure to other immunosuppressive therapies. Certain pathobionts have the capability to stimulate the mucosal immune system, thereby leading to chronic inflammation. On the other hand, commensals are necessary for repair processes in the mucosa and are providing metabolites that are used as an energy source for the colonic epithelium. An increase in pathobionts in combination with a lack of certain commensals might therefore maintain colonic inflammation despite immunosuppressive therapy with systemic steroids in patients with UC.
The investigators therefore plan to investigate the intestinal microbiota in UC patients before and 4 weeks after a systemic corticosteroid therapy and correlate potential alterations of the microbiota to the therapeutic response. Other factors like concomitant UC treatment, disease severity, disease extent and environmental factors will also be correlated to changes in the microbiota.
In the subgroup of patients not responding to steroids and requiring a rescue therapy with infliximab or a calcineurin Inhibitor, the predictive value of microbiota alterations will also be investigated.
If certain bacterial taxa can predict a steroid refractory and an unfavorable disease course, the results of this study will help in identifying possible microbiota based biomarkers for an individualized treatment approach in UC patients in the future.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.
Other names: Aprednisolon, Prednisolut
Time frame: 28 days
To assess if alterations of the fecal microbiota are associated with a failure to respond to steroid therapy within 28 days in patients with ulcerative colitis. The microbiota will be assessed by 16s RNA analysis.
Medical University of Graz
Other
Can Fecal Microbiota Alterations Predict a Refractory Disease Course to Standard Steroid Therapy in Patients With Active Ulcerative Colitis?
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04630028
Colitis, Colitis, Ulcerative
Wilmington, Delaware, United States
View Trial DetailsNCT04779307
Colitis, Colitis, Ulcerative
Phoenix, Arizona, United States
View Trial DetailsNCT04647578
Colitis, Colitis, Ulcerative
Lille, France
View Trial DetailsNCT06049017
Colitis, Colitis, Ulcerative
Anaheim, California, United States
View Trial Details